You are on page 1of 52

M.

PHARM REVISED SYLLABUS (2003-2004) WITH MINOR MODIFICATIONS EFFECTIVE FROM 2004-2005 ACADEMIC YEAR ONWARDS UNIVERSITY COLLEGE OF PHARMACEUTICAL SCIENCES KAKATIYA UNIVERSITY, WARANGAL – 506 009.
SPECIALIZATIONS: 1. 2. 3. 4. 5. Pharmaceutics Pharmaceutical Chemistry Pharmacognosy Pharmacology Industrial Pharmacy (Self – financing) M.PHARM I SEMESTER Marks Lectures Major 1 Major 2 Elective Paper Practical Exams., based on Major 1 Major 2 Seminar Assignment Total: 100 100 100 100 100 50 50 600 4 4 4 Tutorials 2 2 2 Pract. 9 9 -

12

6

18

M.PHARM II SEMESTER Marks Major 1 Major 2 Elective Paper Practical Exams., based on Major 1 Major 2 Seminar Assignment Total: 100 100 100 100 100 50 50 600 Lectures 4 4 4 Tutorials 2 2 2 Pract. 9 9

12

6

18

M.PHARM III SEMESTER Marks Seminar (Pertaining to the topic Of research and work plan Comprehensive viva-voce
Total

50

50
--------100 ----------

Marks Seminar (Experimental Work, Results, discussion and Conclusion) Dissertation evaluation Dissertation Viva-voce Total 50 200 50 ---------------300 ---------------

Important Guidelines: A. There shall be two major subjects and one elective along with two practicals during the first two semesters. B. One seminar will be conducted during each semester (I&II) after the examination. C. One seminar pertaining to the topic of dissertation including concept plan of work, literature will be conducted at the end of IIIrd semester and will be evaluated by minimum of three PG teachers which would include the concerned supervisor. The average marks will be taken into account.

D. Thesis marks will be awarded only by the external examiners. E. Thesis viva-voce marks are to be awarded by the supervisor and external examiner jointly. F. Comprehensive viva shall be conducted at the end of third semester and evaluated by the external examiner and all faculty members within each specialization. G. One assignment related to specialization (related to specific topics and supported by original articles) is given in each of I & II semesters, which shall be evaluated by two examiners. H. The seminars at semester end shall be conducted before all the faculty and PG students and will be evaluated by minimum of three PG teachers. I. There shall be two practical examinations each of six hours duration on two consecutive days at the end of first and second semesters. There shall be one internal examiner for each practical. However, the external examiner shall be common for both the practical examinations.

1. Pharmaceutics I Semester: Majors: 1. Advanced Physical Pharmaceutics 2. Biopharmaceutics & Pharmacokinetics II. Semester: Majors: 3. Advances in Drug Delivery Systems 4. Advanced Pharmaceutical Technology 2. Pharmaceutical Chemistry I Semester: Majors: 1. Advanced Organic Chemistry 2. Advanced Medicinal Chemistry- I II. Semester: Majors: 3. Advanced Medicinal Chemistry – II 4. Advanced Chemistry of Natural Products 3.Pharmacognosy I Semester: Majors: 1. Medicinal Plant Biotechnology 2. Industrial Pharmacognosy -1

II. Semester: Majors: 3. Industrial Pharmacognosy –2 4. Advanced Pharmacognosy 4.Pharmacology I Semester: Majors: 1. Advanced Pharmacology-I 2. Advanced Pharmacology-II II. Semester: Majors: 3. Clinical Pharmacology & Pharmacotherapeutics 4. Screening Methods in Pharmacology & Clinical Research 5.Industrial Pharmacy I Semester: Majors: 1. Quality Assurance and Regulatory Affairs 2. Biopharmaceutics & Pharmacokinetics II. Semester: Majors: 3. Advances in Drug Delivery Systems 4. Advanced Pharmaceutical Technology

4.COMMON ELECTIVES: I Semester: 1. 2. 3. 2. Computer Aided Drug Design Screening Methods in Pharmacology & Clinical Research Drug & Drug Product Stability Pharmaceutical Biotechnology . 4. 3. Drug Regulatory Affairs & Intellectual Property Rights Cell & Molecular Biology Advanced Instrumental Methods of Analysis Cosmetic Technology II Semester: 1.

methods of stabilization. solid state stability. distribution of forces in compaction. Theories of Dispersion: Solid liquid dispersion: adsorption. PHARM. Theories of compaction and compression: Compression. 4.B. phase separation. 6. force volume relationships. methods of accelerated stability testing in dosage forms. Heckel plots. Instrumentation of tablet machines. centrifugal methods. In-vitro-invivo correlations. strength of tablet. kinetics of some decomposition. segregation and its importance. rate equation. Freeze thaw methods. CEU. Sink conditions in dissolution and its importance. (PHARMACEUTICS) I Semester Theory M. Polymer Science: properties of polymers.L. Theory of solubilization and solubilization techniques: solubility and solubilization of non electrolytes. . 3. evaluation. flow properties of powders. and applications of multiple and micro emulsions. Diffusion and Dissolution: Diffusion. models. effects of friction. Applications of polymers in pharmaceutical formulations. crushing strength. temperature and humidity control. H. 5. Dissolution : Basic theories of dissolution. lamination. theory and di-electric properties. Diffusion principles in biological systems. steady state diffusion procedures and apparatus. strategy of stability testing. compaction profiles. wetting. 2. compression and consolidation under high loads. complexation. Kinetics and Drugs stability: Stability calculations. friability. consolidation strength of granules.I. thermodynamics of polymer solution. cosolvents.M. T1: Advanced Physical Pharmaceutics: 1. Preparation. Solid state properties: Crystal properties and polymorphism techniques for study of Crystal properties. 7. Emulsion: Formation and stability of emulsion with special emphasis on electrical theory. solubilization by the use of surfactants. drug derivatisation and solid state manipulation. energy involved in compaction. crystal growth mechanisms and prevention of crystal growth. polymers in solid state. Thermodynamics of diffusion.

Michaelis .. adsorption. complexation. merits and limitations of these approaches.CEU. V). Recent trends. v). c. and half life. Under the following conditions: a. Non invasive methods of estimating pharmacokinetic parameters with emphasis on salivary and urinary compartments. non linear binding. Physico-Chemical properties affecting bioavailability. capsules. Application of these models to determine the various pharmacokinetic parameters pertaining to i) Absorption: (wherever applicable) Absorption rate constant. II. and techniques of enhancing dissolution rate. Intravenous bolus injection Intravenous infusion Single dose oral administration Multiple dose injections Multiple dosage oral administration. surface area. Formulation factors affecting bioavailability of drugs in dosage forms of Tablets. liquid orals and topical dosage forms. gut wall.M.2: BIO-PHARMACEUTICS & PHARMACOKINETICS I. dissolution. total clearance. Bio-availability. and interpretation of results. vi). d. polymorphism etc. One. non linearity of pharmacological responses . Basic concepts of pharmacokinetics: Compartmental models. Concept of Clearance: Organ clearance.T. parenterals. lag time and extent of absorption.I.Menton kinetics characteristics. lung clearance and renal clearance. pH – Partition theory. possible causes of non induction. Absorption half life. IV. e. two and Non compartmental approaches to pharmacokinetics. III. Bioequivalence and Therapeutics equivalence: Designing of bioavailability studies. hepatic clearance. Basic kinetic parameters. iv) Elimination: Over all apparent elimination rate constant. AUC ii) Distribution: Apparent volume of distribution and its determination iii) Metabolism: Metabolic rate constant. Non-liner Pharmacokinetics: Concepts of linear and non linear pharmacokinetics. b.

2 Practicals based on M. infants and geriatrics. factors affecting drug metabolism (genetics. food and beverages on drug action.VI) Time dependent pharmacokinetics: Introduction. physiologically induced time dependency: Chronopharmacokinetics.CEU. Influence of alcohol.I. species and environmental). chemically induced time dependency. VII) VIII) Clinical pharmacokinetics: Altered kinetics in pregnancy.P.I.I. distribution.2 . PRACTICALS M.1 Practicals based on M.P.CEU.CEU. smoking. renal and pulmonary disease states. liver. child birth. classification. metabolism and elimination.T. Drug Metabolism – sites of metabolism. study of drug-drug interactions mediated through absorption. disease.CEU. cardiac.T. kinetics in G. malabsorption syndrome. IX) Drug interactions: Kinetics of drug interaction. Mechanisms of interaction and consequence.I.1 M.I.

1: ADVANCES IN DRUG DELIVERY SYSTEMS A. Micro particulate drug carriers: Liposomes. D.T. Problems of drugs delivery to the brain and targeting to brain. use of polymers in controlled drug delivery. Drug targeting to particular organs: 1. B. 2.PHARM. 2. fabrication. C. Micropspheres. 3. 3.II M. Drug carrier systems targeted to widely dispersed cells. evaluation and applications of the following controlled release systems. Drug delivery to eye. Design. 4. Nanoparticles and Resealed erythrocytes. Drug delivery to respiratory system. Fundamentals of controlled drug delivery system.M. SEMESTER . 1. Proteins and peptide drug delivery. Monoclonal antibodies for drug delivery. 7. Delivery to Macrophages. 2. 2. Parenteral controlled release drug delivery systems Implantable therapeutic systems. Ocular and intrauterine delivery systems. 4. Neosomes. Drug targeting in neoplastic diseases.CEU. 3. Controlled release oral drug delivery systems. Delivery to lysosomal storage diseases. Delivery to lymphoid cells of Immune network. pharmacokinetic and Pharmacodynamic basis of controlled drug delivery. 6. Theory of mass transfer. Transdermal therapeutic systems and iontophoresis. 1. 5. . 1.II. Bioadhesive drug delivery systems. Biochemical and molecular biology approaches to controlled drug delivery.

(e) Aerosols: Advances in propellants. microbial environmental monitoring. dry powder inhalers. Aseptic Processing Operation: Introduction. Formulation Development: (a) Solid dosage forms: Improved production techniques for tablets: New materials. contamination control. 3.T. solid state properties. compression machines.II. manufacture and quality control. equipments improvements. ADVANCED PHARMACEUTICAL TECHNOLOGY 1.CEU. Drug excipient compatibility. (b) Powder dosage forms: Formulation development and manufacture of powder dosage form for internal and external use including inhalation dosage forms. process. Solubility and partition coefficient. coating machines. (d) Parenteral dosage forms: Advances in materials and production techniques. characterization of aseptic process. microbiological testing of water. physics of tablet compression and computerization for in process quality control of tablets. sterilizers and aseptic processing. Solubility and dissolution.M. preformulation parameters. high shear mixers. 2. theoretical evaluation of aseptic operations. (c) Liquid and Semi-solid dosage forms: Recent advances in formulation aspects and manufacturing of monophasic dosage forms. Preformulation studies: Goals of preformulation. metered dose inhaler designs. Modern concepts in rheology. filling machines. selection of containers and formulation aspects in aerosol formulation. coating techniques in tablet technology for product development. microbiological air testing. media and incubation condition. . recent advances in formulation aspect and manufacturing of suspensions and semisolid dosage forms. methodology.2.

Scale-up Techniques: Effect of scale up on formulation. Liquid dosage forms. Optimization techniques in pharmaceutical and processing Optimization parameters. Testing programme and method. development and optimization of in-vitro test systems to evaluate and monitor the performance of different types of dosage forms. strip packing. selection and evaluation of suitable equipments. application of statistical techniques in product development and evaluation including quality control.CEU. packs for tablets. 9.CEU.CEU.II. Packaging Technology: Packaging materials. drying. compression. FDA regulations. Drug information profile. Quality control: Process and Dosage form: Process control: Control of manufacturing process. statistical quality control. capsules. process parameters like mixing. 6. 7. statutory requirement and procedure for documentation.P. Sterile products. Closures and containers units of dose packaging. and process. control charts.T. Dosage form control. relevance and importance of in-vitro/invivo associations at every stage of product development and manufacture. 1 M. product identification system. blister packing.T. 2 . Documentation: Importance of documentation. Adulteration and misbranding. 8. 2 Practicals based on M. Equipment.P. regulatory evolution and current thinking on this aspect. Validation of analytical methods. Process validation of raw materials. of automated process control.II.CEU. Process Validation Regulatory basis. 5. stability.II. critical examination of documents.II. 1 Practicals based on M. design. statistical design and other applications.4. validation of solid dosage forms. PRACTICALS M. granulation. ointments and aerosols. packaging. coating.

compounds with two or more unequal asymmetric carbon atoms. Mechanism of electrophilic addition and substitution reactions. 2.CHEM. III. 3. Lithium aluminium hydride(LAH) & Sodium borohydride. N-Bromosuccinimide (NBS) Lead tetra acetate (LTA) Diazomethane (DM) .M. (iv) Configuration: Definition.Terpenes. compounds containing like asymmetric carbon atoms. physical and chemical properties and important synthetic applications of the following reagents: 1. notation. Hofmann’s rule. (c) by racemization and (d) by chemical transformation. absolute configuration and Relative configuration.I (PHRAMACEUTICAL CHEMISTRY) M. Wolf Rearrangement. substitution and plymerisation reactions. Factors influencing Nucleophilic substitution and Elimination reactions with suitable examples. Electrocyclic Reactions. compounds with asymmetric carbon atoms in branched chains. Elimination.T.I. 4. (v) Synthesis of optically active compounds: Stereoselective synthesis and stereospecific synthesis (vi) Stereo-chemistry of Nitrogen Compounds: II. (a) by mixing. substitution Vs. Hofmann’s Vs. Saeytzef’s rule. pinacol-pinacolone Rearrangement. Stereochemistry of Carbon and Nitrogen Compounds: (i) Optical Isomerism (due to asymmetric or chiral carbon atoms) Compounds with one asymmetric carbon atom. mechanism of nucleophilic addition and substitution (SN1 & SN2 ) reactions. (b) by synthesis. mechanistic features of E1 & E2 reactions.1 ADVANCED ORGANIC CHEMISTRY I. (ii) Stereo-chemistry of Biphenyls (iii) Racemic modification: Nature of racemic modifications. PHARM. Molecular Rearrangements: Claisen allylation. Wagner Meerwein Rearrangement of Bicylic C10 . formation of racemic modifications. Reagents and their synthertic applications: Methods of preparation. Pericyclic reactions and Sigmatropic Reactions. Saeytzef’s. SEM . Elimination Reactions. Mechanisms of Organic Reactions: Mechanism of free radical addition.

A mention of natural products used in cancer treatment.I. significances of various types of isomerism with respect to pharmacological activity.I.CHEM. Vinca alkaloids (Vincristine and Vinblastine) podophyllum and paclitaxel. II. clinical and biological uses.I. PRACTICALS M. CHEMI. IV.CHEM. moleculer modifications.P. V.Abnormal protein factors. Vasopressin and Oxytocin. leads from natural products. prodrug and soft drug concepts. genetic factors and nutritional disorders. toxicity and clinical significance of phenothiazines. sex hormones & analogs.I. Synthesis of clinically useful drugs of each of the above classes.2: Practicals based on theory M. M. antimetabolites. Genesis of New Drugs: Source. III. endogenous amines and related substances. synthesis and evaluation methods. Chemothorapy of Cancer: A detailed classification of antineoplatic agents. Mechanism of action. Phenothiazines: chemistry.CHEM. faulty energy metabolism. b) Histamine (H1 and H2) and 5-HT.T2 . The important pharmacological activities of phenothiazines.P: 1 Practicals based on theory M.I. Pscychopharmacological agents: a) Biochemical basis of mental disorders:. their SAR studies. c) Thyroid Hormones (T3 and T4). Theoretical aspects of drug design: Structural features and pharmacological activity.T.2 ADVANCED MEDICINAL CHEMISTRY – I I. mechanisms of action of different classes. concept of isosterism. Drugs Related to Hormones and other autocoids: A study of the following hormones and other autocoids with a special reference to their agonists and antagonists: a) Peptide Hormones: Insulin. T. and antibiotics. tricyclic antidepressants and Miscellaneous compounds.1.CHEM. random screening. side effects and their SAR studies.M. SAR of phenothiazines. Alkylating agents and radiomimetic agents. b) Antidepressants: MAO inhibitors.

Free Wilson analysis and their relationships. II. their types. Acetylcholine esterase (AChE) Inhibitors. c) Antiviral agents. Miscellaneous Classes of Drugs: Recent advances in the following classes of drugs: a) Proton-pump inhibitors as antiulcer agents. mechanisms of drug action (Receptor theories). N-and S-oxidations catalyzed by flavin monooxygenase. related drugs and their pharmaceutical significance: a) b) c) d) e) P.1 ADVANCED MEDICINAL CHEMISTRY-II I.G. lipophilicity. dosage-response relationships. c) Drug conjugation pathways (Phase II metobolism). IV. Rational Drug Design: QSAR: parameters involved in QSAR.M.PHARM. d) β – Adrenergic blockers. Synthetase (cycloxygenese and lipoxygenase inhibitors) Phosphodiesterase (PDE) inhibitors. Quantitative models. polarisability. III. location and isolation. Drug Metabolism: a)Introduction. Angiotensin converting of Enzyme (ACE) Inhibitors. types of interactions with the drug molecules. Enzyme Inhibitors-I: A detailed study of the following types of enzyme inhibitors. linear relationships and applications of Hansch and Free-Wilson analysis. Carbonic anhydrase inhibitors. electronic and steric parameters. and Nonmicrosomal oxidations. b) Drug bio-transformation pathway (Phase I metabolism): Human hepatic cytochrome P450 enzyme system.CHEM. Theoretical Aspects of Drug Action: Receptors. II SEMESTER M. b) Immunosuppressive and immunostimulant agents.T.II. oxidation catalyzed by cytochrome P450 isoforms. Hansch analysis. V. .

Hyoscyamine and Hyoscine. a) Alkaloids of Opium: Structure elucidation of Morphine. c) Alkaloids of Vinca rosea . antidiarrhoeals. Alkaloids: Study of the following classes of alkaloids. antitussive agents. Opioid receptors.2 ADVANCED CHEMISTRY OF NATURAL PRODUCTS (Theory) I. stereochemistry and numbering. d) Alkaloids of Ergot: Classification. Structural modifications and semisynthetic derivatives. relative potencies.CHEM.II. Structure elucidation of Atropine. structure activity relationships in morphine molecule. . Structural considerations of Atropine. New insights on steroid receptors. b) Alkaloids of Atropa belladonna . Endorphines and Enkephations. Structures. therapeutic uses of ergot alkaloids and derivatives (vinyl and methylsergide). II Steroids: a) Steroid nomenclature. Development of morphine analogues based on SAR. Structure elucidations. chemical and physical properties of steroids. Vincristine and vinblastine. PHARMACY (PHRMACEUTICAL CHEMISTRY) M.II SEMESTER M. changes to modify pharmacokinetic properties of steroids. morphine antagonists. Homatropine. Structure elucidation of Erogometrine.T. Atropine. Therapeutic uses.

Nogalamycin and . uses of the following antibiotics. chemical degradations. β – Lactamase resistance. structures. Daunomycinol and AdriamycinolTheir semisynthetic derivatives: the 4’-Deoxy and 4’-epidoxorubicines. b) Anticancer Antibiotics: Source. βsitosterol and Diosgenin. Antipseudomonal cephalosporins. Nomenclature. ii) iii) Aureolic acid group – Mithramycin The Bleomycines. therapeutic uses. Stigmasterol. III Antibiotics: a) Cephalosporins: Historical background. mechanism of action.spectrum of activity. Anthracyclines – Daunorubicin and Doxorubicin – Their metabolic products: menogaril. cephamycins. f) Steroids in the treatment of cancers. Natural and semi- synthetic cephalosporins. classifications. regimen. i) Actinomycines – Dactinomycin. e) Anabolic Steroids: Structures. SAR. structures.b) Sources and structure elucidation of cholesterol. description of the structural features. uses. Mitomycins and streptozocin. structure. mechanism of action. structure-activity relationships. c) Steroidal Anti-inflammatory Agents. d) Steroidal Anti-fertility agents: Structures. sources and structures of related steroids – Ergosterol.

c) Phototherapy: sources and structures of psoralens.1.II.II.P. their uses and mechanism of action.2 : Practical based on M.CHEM. (Detailed list of Experiments included) . protopanaxadiols and triols.CHEM. uses.IV A Brief Account of the Following: a) Anticancer Agents of Plant Origin: Sources and structures of podophyllotoxin.T.CHEM. PUVA therapy in psoriasis and ritiligo. Photodegradation of 8 – methoxypsoralen.1: Practical based on M.P. b)Ginseng: Historical background.T. structures of Ginsenosides. khellin and KUVA therapy xanthotoxin in the treatment of psoriasis.CHEM.II.2. M.II. Taxol and camptothecin. their semi synthetic derivatives. PRACTICALS M.

Sennosides from Senna h. Glycyrrhizin from Glycyrrhiza glabra k. Hesperidin from orange peel i. Curcumin from Turmeric e. a. Plumbagin from plumbago rosea l. purification and characterization of some of the following phytoconstituents. Embelin from Embelia ribes j. Piperine from Black pepper b. Isolation. Flash Chromatography and Vacuum liquid chromatography in the isolation of some of the above mentioned phytoconstituents. Strychnine and Brucine from Strychnos nuxvomica c. . The use of Column chromatography.M. Caffeine from Tea powder d. Tannins from myrobalans II. Pectin from orange peel m. PHARM (PHARMACEUTICAL CHEMISTRY) II SEMESTER ADVANCED CHEMISTRY OF NATURAL PRODUCTS (PRACTICALS) I. Bixin from Bixa orellena f. Diosgenin from Dioscorea tubers g.

cryopreservation and retention of biosynthetic potential in cell cultures. Genetic transformation applications.PAHRM. Flavanoids. E. techniques. Protoplast fusion and cultures. B. Anthraquinone and Saponin glycosides. Effect of cultural practices.1I . F. G.MEDICINAL PLANT BIOTECHNOLOGY A. Screening and selection of high yielding cell lines. effect of immobilization on secondary metabolism and realization of chemosynthetic potential in immobilized cells. cellular totipotency. Types. Organogenesis and embryogenisis. Imidazole.M. Biotransformation. Historical perspectives. and Isoprenoid compounds of pharmaceutical significance. immobilization techniques. bioreactors. Secondary metabolism in tissue cultures with emphasis on production of medicinal agents and its impact in pharmacy. (PHARMACOGNOSY) I SEMESTER MAJOR COURSES M. quionoline.COG. Sterols. Biogenesis of tropane. methods. Applications in pharmacy and allied fields.I. industrially potential tissue culture systems for pilot and large scale cultures of plant cells. nutritional requirements and growth of plant tissue cultures. D. Isoquinoline and Indole alkaloids. prospects for development of plant biotechnology as source of medicinal agents. micropropogation of medicinal and aromatic plants. artificial seeds.T. . Techniques employed in elucidation of biosynthetic pathway. Genetic stability of tissue cultures. Immobilized plant cell culture systems. Hairy root cultures and their C. precursors and elicitors on production of biomedicinals.

Clove. Pharmaceutical gums. Pharmaceutical aids: Profile for manufacture and commerce of Papain.I. B. PRACTICALS M. C.P. Japanese Mint. Patchouli. nutritional and precursor factors of influencing production of metabolites in tissue cultures. Disease management of medicinal and aromatic plants. Technology for commercial scale cultivation and processing of following aromatic plants: Lemongrass.T. Starch. . Palmarosa.COG. Study of their growth profiles. Celery.I. Representative exercised based on extraction of pharmaceutical aids and volatile oils listed in theory.COG. Sandal. 2. Cinnamom Jasmine. Establishment of some hairy root cultures and study of their growth and bioproductive profile. Industrial Pharmacognosy – I 1.P.M. 3. Davana. 2.1.I. Dill. Pectin.2 INDUSTRIAL PHARMACOGNOSY-I A. Basil. D. Experiment for exogenous. M. Plant growth regulators and their applications in pharmacy. Medicinal Plant Biotechnology 1. Exogenous and endogenous factors influencing production of crude drugs. Geranium. Anise. Rose.2. Hops. Phytochemical screening of plant extracts : Preparation of extracts and detection of phytoconstitutents by different techniques. Cardamom. Variability in crude drug activity. Vetiver.COG. Absorbent cotton and Gelatin. Representative exercises based on establishment of callus and suspension cultures. Aseptic transfer of bio-mass. Phytochemical screening of crude drugs : Extraction and qualitative evaluation for drug constituents.

Opium poppy. quinine.II semester M. Preparation of standardized extracts suitable for incorporation in solid dosage forms like tablets. Immunomodulatory herbal drugs.II. Ammi majus. C. packaging and approach to quality control of herbal formulations. taxol.2. caffeine. Periwinkle. A review of hepatoprotective. Emerging plant drugs: anti-hypertensive. Herbal formulations : Types of herbal formulations. Cinchona. podophyllotoxin. Senna. Digitalis. anti-HIV and anti-diabetic plant drugs. Psyllium. Steroid bearing Solanums.COG. Guggul. solasodine. scopolamine. Belladonna. Biomedicinals of recent discovery. Neem. digoxin. . emetine.COG. B. E. Medicinal Yams. Liquorice. ergot alkaloids. berberine. Henbane. antimalarial and (b) (c) (d) Current status of anti-cancer. shark-liver oil. Profiles for commercial cultivation technology/and post-harvest care of following medicinal plants : Ashwagandha. Manufacture. Current status of regulatory affairs for herbal formulations. Herbal cosmetics and herbal teas.II. Recent trends in poly-herbal medicines. Ergot. Safed Musli. ADVANCED PHARMACOGNOSY (a) Problems encountered in and prospects of discovering new drugs from plants. Saffron. ginsenosides. Ipecac. withanolides. M. Bioevaluation of herbal drugs. World Health Organisation guide lines for herbal drugs including standards for pesticide residue / aflatoxins. capsules etc.T. Bioactive Compounds: Occurrence. Natural substances as raw materials in drug synthesis.1 Industrial Pharmacognosy-II A. cod-liver oil. D. GMP for herbal drug formulations. Papaya. atropine.T. Aloe. Methodology for extraction and chemical nature of sennosides.

chemical and biological techniques of evaluation of plant constituents/extracts. GLC and HPLC.COG.II.1.2. cytotoxic. P. Flourimetry and colorimetry. II. 2) Preparation of selected poly-herbal formulations. Current status of plants used in alternative system of medicines. Uses of UV. Recent trends in utilization of vegetable laxatives and vegetable bitters. ADVANCED PHARMACOGNOSY (Practical) 1) Representative exercises based on physical. Hallucinogenic. antimicrobial and anti-inflammatory compounds. Endangered species of medicinal plants. NMR and mass spectrometry in the structural elucidation of natural products. P.(e) Application of various chromatotgraphics techniques and spectrometry to natural products: TLC. . Drugs and Pharmaceuticals from marine source (Marine Pharmacognosy) with special reference to cardiovascular. M. IR. teratogenic and other toxic plants. INDUSTRIAL PHARMACOGNOSY – II (PRACTICALS) 1) Representative exercises based on extraction of bioactive compounds listed in theory. (f) (g) (h) (j) II SEMESTER M.COG. Natural sweetening agents and coloring agents. allergic.

Depression & Mania 3. B. Anxiety & Psychosis 2.1. Migraine 5. Pain C. (PHARMACOLOGY) M. Drugs acting on the Central Nervours System. I. C. Drugs used in the treatment of 1. CNS degenerative disorders 6.I SEMESTER M. Epilepsy 4. Agents acting at NMJ and autonomic ganglia E. Sympathomimetic antagonists. A. Muscarinic receptor agonists & antagonists.COL. Autonomic & somatic nervous systems. Neurotransmission and CNS. A. Catecholamines and adrenergic II. Drug addiction & abuse . drugs.T.I. Anticholinesterases D. B. Parkinson’s Disease 7.PHARM. ADVANCED PHARMACOLOGY – I Drugs acting at synoptic and neuro effecto junctional sites.

Drugs acting on the blood & blood forming organs A. thrombolytics & antiplatelet drugs. Growth factors B. Hyperlipidemia IV. CHF 4.III. . Myocardial Ischemia 2. Drugs used in the treatment of 1. Hypertension 3. Diuretics B. Drugs affecting renal and cardiovascular function A. Anticoagulants. Renin & Angiotensin C.

Oral hypoglycemic agents. Chemotherapy of A. ADVANCED PHARMACOLOGY – II I. Agents for control of acidity and antiulcer drugs B. Progestins and Androgens.T. Eicasonoids & PAF C.1.COL. Estrogens.COL. M. Bradykinin & their antagonists B.T. Antiinflammatory.1. Drug therapy of Inflammation A. .I. Neoplastic diseases IV.M. Drugs affecting gastro intestinal function. Malaria B.2.1 Practicals based on theory M. Autacoids.I.2 Practicals based on theory M.COL. (i) (ii) (iii) Fluroquinolones Cephalosporins and other newer agents Antifungal & antiviral drugs including Anti HIV drugs. Histamine. Microbial infections.P.P. C. Emetics & anti emetics.COL.2. PRACTICALS M.COL. A. analgesic & antipyretic agents D. V. III.1.I.T. II. Antiasthmatic agents.

III. psoriasis. Parkinson’s. arrhythmias. Clinical Pharmacokinetics i.1. glaucoma. tract infections. fungal and HIV infection. TB. IV. rheumatoid arthritis. depression. Therapeutic drug monitoring iv. Pathophysiology and drug therapy of the following disorders. g.PHARM (PHARMACOLOGY) M. Population pharmacokinetics II. Revision of basic concepts B. Clinical Pharmacology & Pharmacotherapeutics I.i. Pregnancy & Lactation V. respiratory. epilepsy. migraine hypertension. Dose – response in man ii. menstrual disorders. Geriatrics B. endocarditis. lymphomas. Drug Interactions and ADR monitoring. Schizophrenia. I. leukemia.T. leprosy. . atherosclerosis. urinary. menopause. Influence of renal and hepatic disease on pharmacokinetics iii. myocardial infaraction. Adverse Drug Reactions.COL. Pediatrics C. Alzheimer’s diseases. solid tumors. Principles of Pharmacokinetics A. anxiety. angina pectoris.II SEMESTER M.II. Pharmacogenetics: Interracial and individual variability in drug metabolism. Drug therapy in A.

antiepileptics. transgenic animals and other genetically prone animal models. antidepressant drugs. molecular biology techniques.II. Preclinical and clinical models employed in the screening of new drugs belonging to following categories Antifertility agents.COL.T. vasopressin. sedatives. b. Introduction to biostatistics.M. patch-clamp technique.2.COL.ELE. anthelmintics.P. hyaluronidase. d-tubocurarine.2. Antipsychotic agents. infarction.II. Screening Methods in pharmacology and clinical Research practicals based on M. International guidelines (ICH recommendations). Acetylcholine.II. cardiac stimulants. antiulcer agents. in-vitro models. techniques and strategies used in new drug discovery. antidiabetics. muscle relaxants (both central and peripheral). PRACTICALS M. c. LD50 and TD values. models for status epilepticus.T. 4. antiParkinsoinan agents.II. cell-line. Principles of toxicity evaluations. Alternatives to animal screening procedures.T. experimental models and statistical designs employed in biological standardization. . 3.COL. bronchodilators.T2. corticotrophine. ED50. official bioassays. Regulations for laboratory animal care and ethical requirements. Clinical pharmacology and pharmocotherapeutics practicals based on M. Drug discovery process: Principles.COL. insulin.II.II. Bioassays: Basic principles of bioassays. intracerebroventricular and other newer techniques of drug administration and development. & M. eicosanoids. Adrenaline. antihistaminics. parametric and non parametric tests. antianxiety agents. rabies and plague. HCG. Biological standardization of vaccines and sera. pertussis.1. antiatherosclerotic drugs. analgesics and anti-inflammatory agents. hypnotics. antimalarials. 2.COL.P. High throughput screening.1. M. cardiotonic agents. parasympathomimetics. nootropic drugs. sympathomimetics. human genomics. a. oxytocin. SCREENING METHODS IN PHARMACOLOGY AND CLINICAL RESEARCH 1. antiarrhythmic agents. robotics and economics of drug discovery.2.

Dosage form control.I. Drug information profile. product identification system. sterile products. Testing programme and methods. validation of solid dosage forms. Process Validation: Regulatory basis. Optimization techniques in Pharmaceutical and Processing: Optimization parameters. Process validation of raw materials. Design and instrumentation of the buildings and their maintenance as per current good manufacturing practices for the bulk production of different pharmaceutical dosage forms. 6. liquid dosage forms. production optimization and process validation of raw materials and analytical methods. Installation.1: Quality Assurance & Regulatory affairs: 1. statistical quality control. . (Industrial Pharmacy) I–SEMESTER M.M. statutory requirement and procedure for documentation. ISO 9002 and documentation. the relevance and importance of invitro/in-vivo associations at every stage of product development and manufacture. Documentation: Importance of documentation. design development and optimization of in-vitro test systems to evaluate and monitor the performance of different types of dosage forms. 5. New Drug Application: Steps involved in the development of a new drug. control charts of automated process control. with a special reference to sterile products and solid dosage form. Good manufacturing practices. 4. validation and maintenance of typical equipment used in the bulk manufacture and packaging different dosage forms with a special reference to GMP models. equipment and process. the regulatory evaluation and current thinking on this aspect.T. New drug application as per WHO guidelines and abbreviated NDA. 2. validation of analytical methods. CGMP. Quality Control: Process and Dosage form: Process control: Control of manufacturing process.IND. application of statistical techniques in product development and evaluation including quality control. Requirement and guidelines on clinical trials for import and manufacture. Adulteration and misbranding. 8. critical examination of documents. 3. statistical design and other applications. GLP.Pharm. 7.

Industrial efficiency testing. Monitoring and prevention systems. . Stability Studies: ICH guidelines and WHO guidelines and stability protocols for dosage forms.9. 10. mechanical and electrical equipment. chemicals and pharmaceuticals. Industrial Safety: Industry hazards due to fire accidents.

and interpretation of results. lung clearance and renal clearance. Basic concepts of Pharmacokinetics: Compartmental models: One. iv. Intra venous bolus injection Intra venous infusion. pH-partition theory. Basic kinetic parameters. and techniques of enhancing dissolution rate. surface area. Elimination: Over all apparent elimination rate constant and half life. Metabolism: Metabolic rate constant and its determination. lag time and extent of absorption. capsules. Single dose oral administration. polymorphism etc. total clearance. adsorption. ii. non linearity of pharmacological response. liquid oral and topical dosage forms. Physico-Chemical properties affecting bioavailability.I. Concept of clearance: Organ clearance. complexation. i. V) Non-liner Pharmacokinetics: Concepts of linear and non linear pharmacokinetics. Non invasive methods of estimating pharmacokinetic parameters with emphasis on salivary and urinary compartments. Multiple dosage oral administration. Application of these models to determine the various pharmacokinetic parameters pertaining to.CEU.. two and non compartmental approaches to pharmacokinetics. Absorption: (wherever applicable) Absorption rate constant. Michaelis . gut wall clearance.IND.M. iii. Bio-availability. Under the following conditions: a) b) c) d) e) v.2: Bio-Pharmaceutics & Pharmacokinetics I. vi.Menten kinetics characteristics. III. Formulation factors affecting bioavailability of drug in dosage forms of tablets. AUC. hepatic clearance. Absorption half life. Distribution: Apparent volume of distribution and its determination. possible causes of non induction. parenterals. II. Bioequivalence and Therapeutic equivalence: Designing of bioavailability studies. . Recent trends.I. IV. Multiple dose injections. dissolution.2 & M. non linear binding.T. merits and limitations of these approaches.T.

Practicals based on M. M.P. factors affecting drug metabolism (genetics.IND.1. distribution.2. smoking. classification. .T. infants and geriatrics. child birth.I. renal and pulmonary disease states. Practicals based on M.I.VI) Time dependent Pharmacokinetics: Introduction. IX) Drug interactions: Kinetics of drug interaction. species and environmental).I. Mechanisms of interaction and consequence. malabsorption syndrome. Drug Metabolism – sites of metabolism.IND.P. food and beverages on drug action.IND. study of drug-drug interactions mediated through absorption. disease.T. Influence of alcohol. physiologically induced time dependency: Chronopharmacokinetics. liver.2.IND. metabolism and elimination.I. chemically induced time dependency. cardiac.1. PRACTICALS M. VII) VIII) Clinical Pharmacokinetics: Altered kinetics in pregnancy. kinetics in G.I.

SEMESTER . Lung delivery systems. Transdermal module. Use of polymers in controlled release of active agents. Types and structure of polymers.T. 2. Antibody-drug conjugates. Resealed erythrocytes. Site specific proteins. Drug targeting principles and approaches: Active and passive targeting. implantable therapeutic systems. Overview of delivery systems. Parenteral dosage forms. Niosomes. Radioisotopes. Receptor saturation. prodrugs. Module for gastrointestinal tract. Biodistribution of antibody.II M. Liposomes. Transmucosal systems and mucoadhesive systems. Review of Fundamentals of controlled drug delivery systems Fundamentals. Polymer degradation. Tumor targeting. . 5. Delivery of peptides/proteins/Biotechnology Drugs: formulation aspects: Preformulation studies and problems: Protectants. Limitations of antibody targeting. Intramuscular injections. Evaluation of recombinant proteins. Drug loading. Microspheres. Ocular systems. Reservoir devices.II.IND. Pharmacokinetic/Pharmacodynamic basis of controlled drug delivery. intravaginal and intrauterine systems. Stability problems. Cellular-particulate systems. Magnetic microspheres. Further prospects. Systems utilizing ion exchange resins. 4. Module for eye. Biocompatibility of polymers and methods to improve it. rationale of sustained/controlled drug delivery. Nasal delivery. Bone marrow targeting. delivery kinetics. factors influencing the design and performance of sustained/controlled release products. Systems utilizing dissolution. Design and fabrication of controlled release drug delivery systems: Principle involved and Formulation of : Oral dosage forms – Diffusion system. Carrier Based delivery system: Principle involved and Formulation of : Microparticulate drug carriers. Multiple Emulsions. Colon specific systems. Brain targeting.1: Advances in drug delivery systems 1. 3. Osmotic systems.

Controlled release microparticles for vaccine development. Absorption enhancers. Vaccine delivery: Evidence and mechanism of uptake and transport. Single dose vaccine delivery systems using biodegradable polymers. Lipid carrier systems. Monoclonal antibodies. Delivery systems used to promote uptake.6. Peyer’s patches. Oral immunization. Common mucosal immune system. .

(a) (b) 3. Modern concepts in rheology. dry syrups and Semi-solid dosage forms. process. Effect of particle size. Recent advances in formulation aspects and manufacturing of suspensions. moisture content and lubrication on the strength of tablets.2: ADVANCED PHARMACEUTICAL TECHNOLOGY 1. production and evaluation of hard and soft gelatin capsules. coating machines. Solubility and Partition coeffcient. Recent advances in dissolution testing. Excipients used in pharmaceutical dosage forms: Polymers Properties and selection criteria for various excipients like surfactant. sink condition and its importance. Automation in dissolution. types of dissolution equipments. Physics of tablet compression computerization for in process quality control of tablets. viscosity promoters. Solubility. plasticizers. Dissolution: Theory. Preformulation parameters. “In-vitro / In-vivo” correlations. Mathematical models. Formulation Development: (a) Solid dosage forms: Improved Production techniques for tablets: New materials. types of tablets and their manufacture Formulations. Powder dosage forms: Formulation development and manufacture of power dosage form for internal and external use including inhalations dosage forms. (c) Liquid and Semi-solid dosage forms: Recent advances in formulation aspects and manufacturing of monophasic dosage forms. . preservatives.M. compression machines. Preformulation studies: (A) Goals of preformulation. coating materials. Coating techniques in tablet technology for product development. Solid state properties. flavors and colours. Drug excipient compatibility. (B) 2. diluents. high shear mixers. Methodology. equipments improvements.IND.T. (b) Compaction and compression: compaction of powders with special reference to distribution and measurement of forces in the powder mass undergoing compression.II.

ointments and aerosols. strip packing. metered dose inhaler designs.IND.II.II.II. selection of containers and formulation aspects in aerosol formulation.II. Pilot plant and scale-up pharmaceutical dosage forms. PRACTICALS M. 5.T. sterilizers and aseptic processing. media and incubation condition. blister packing.2: Practicals based on theory M.P. dry powder inhalers.(d) Parenteral dosage forms: Advances in materials and production techniques. M. FDA regulations. techniques for the production of different 6. 4.P. Manufacturing of small and large volume parenterals and quality control. microbial environmental monitoring. contamination control. characterization of aseptic process. . theoretical evaluation of aseptic operations. packaging of tablets.1: Practicals based on theory M.2.IND. unit dose packaging. capsules. filling machines. closures and containers. Aseptic processing operation: Introduction.IND. (e) Aerosols: Advances in propellants.T. Packaging Technology: Packaging materials.1.IND. microbiological testing of water. Microbiological air testing. Manufacture and quality control.

DRUG REGULATORY AFFAIRS AND INTELLECTUAL PROPERTY RIGHTS 1. united states. Analytical method validation as per. 3.Pharmaceutical development: Preformulation studies. Indian and other regulatory authorities. dosage form in their final packaging. ocular preparation. regulatory requirements as per European community. united slates. regulatory requirements as per European community. data requirement for new drug as per regulatory requirements as per European community. united states. Indian and other regulatory authorities. bulk active drug substances. 4. Biopharmaceutics: Introduction. regulatory requirements as per European community. biological test elastomer test. regulatory requirements of European community. Extension of shelf life after authorization of drug. Regulatory guidelines for packaging materials. scientific and technical background to the design of stability testing.I. documentation. test and evaluation of packaging materials. inspection requirements. different testing parameters and . international aspects of excipients approval as per guidelines of all the territories.ELE. manutacturing formula. definition. 2.1. manufacturing process. dosage form. introduction to solid.ELECTIVES OF I SEMESTER M. storage. Manufacturing: Introduction. pharmacokinetic and toxicokinetic validation. Stability testing: Introduction. liquid and semi-solid dosage forms. and Indian regulatory authorities. regulatory guidelines for active ingredients. Indian and other regulatory authorities for manufacturing information. international harmonization and current guidelines.T. process. validation of manufacturing process. Indian and other regulatory authorities for testing of new active substances. stability. controlled release prearation. microbiological test and evaluation of closures. equipment. united states. factors related to formulation. united states. injection.

guidelines as per European community. factorial design. regulatory requirements. purpose. Indian and other regulatory authorities documentation. documentation. Clinical study design. guidelines as per European community. statistical analysis. 6. united states. 6. design documentation. united states. Japanese. genetic and environmental factors. current guidelines and developments as per regulatory requirements of European community. statistical analysis of clinical data. united states. clinical bioavailability. presentation and interpretation. Indian and other regulatory authorities. united states. Indian and other regulatory authorities. Indian and other regulatory authorities. and phase IV studies. Phase III. presentation. Japanese. Phase II.standards as per regulatory requirements of European community. Preclinical aspects of biopharmaceutics. ethnic. Clinical trials: definition. study design. documentation. 5. . presentation and interpretation. international scenario and Indian scenario. Clinical pharmacology and Pharmacodynamics: Introduction. phase I. Intellectual property rights: Introduction. pharmacokinetics in men. presentation. application.

Enzymes. Endo membrane systems. Extracellular environment B. Nucleus and Cytoplasmic matrix A. Organization of Pro and Eukaryotes II. Molecular Organization and Genome A. Transcription: Mechanism. surface. Concept of Gene B. CELL AND MOLECULAR BIOLOGY I. Cell types C. transport B. Cell wall. Cell growth and Division. The cell doctrine B. Replication: Mechanism. Chromatin and Chromosomes C.2. Nucleus B. Structural Organization of life. B. V. A. DNA Replication and Transcription A. aggregation.ELE. . VI.T. Transmembrane signals C.I. Cell membrane: Structure and Functions A. projections C. Cytoplasm & cytoskeleton D. IV. Enzymes. Antigen mediated responses. Cell recognition. Molecular models. Surface artchitecture A. III.M. Behaviour of the Genome VII.

. Chromosomal aberrations XI. Carcinogenesis. Plasmids B. X. B. Molecular basis of mutation. Mechanism of Protein Synthesis. Theories of aging. Genetic recombination A. IX. Types of tumors. Transduction and Transformation. Souce of variations. Etiology of cancer C. XII. Molecular biology of aging and cancer. A. Levels and mechanism of diffentiation. types of mutations B. Factors affecting differentiation B. Cell differentiation A.VIII. A.

I. knowledge of instrumentation and application with regard to drug analysis. Methods of validation. metabolite analyses. EI & FAB MS) isotopic abundance.. Laboratory maintenance standard operating procedure (SOPs). III. IV.T.3.P.L. Super critical liquid chromatography ii) II. and special methods based on the following.C.ELE.A. i) Theory.P. knowledge of instrument and basic principles of : 1 H Nuclear Magnetic Resonance Spectroscopy (1H NMR): Concepts of chemical shift. decomposition product identification and estimation. ADVANCED INSTRUMENTAL METHODS OF ANALYSIS I. Introduction. Chromatographic methods (Gas – chromatography including GC-MS. spin spin coupling.C. shielding and deshielding effects. Nitrogen rule.T. base peaks etc.C. molecular on fragmentation. Ultraviolet – visible spectrophotometry Infrared spectrophotometry Fluorimetry I. Special Techniques: a) b) c) d) Immunological methods (RIA – ELISA) H. . High performance liquid chromatography. Mass Spectroscopy.P. Good laboratory practices (GLP). different techniques of ionization (CI. Theory. H.M. coupling constant.B. electrophoresis (gel and capillary) with an emphasis on specific examples in biological assay methods.

Bassler. Silverstein. 3. John Dyer Organic Spectroscopy W. Morrill Pub: John Wiley and Sons Spectroscopic identification of organic compounds.BOOKS RECOMMENDED M. Chemistry) Herald Gunther. T.T.3 1.ELE.M. Kemp NMR spectroscopy (Basic Principles.C.C. Spectroscopic identification of organic compounds.I. G. R. 4. . (John Wiley and Sons) concepts and application in 2.

moisturizers. Setting lotion. 4.Shelf-life determination of Cosmetic products. cream bases. sunscreen products. on product stability. like surfactants. Colour Cosmetics Introduction. temperatures etc. Shampoos. 6.M. Effects of environmental factors like light.4 COSMETIC TECHNOLOGY 1. Knowledge of generic and proprietary products. Tooth paste.T. Preformulation studies: Preformulation studies and stability testing of Cosmetic products. 5. Hair creams. 2. face make-up eye make-up. Hair Care Products Introduction. colours. 3. Skin Care products Introduction. Conditioners. perfumes. 7. Aerosol propellants. Dental product: Dentifrices. Oral rinses. Hair structure. nail polish. anatomy and physiology of skin. Tooth powder.ELE. formulation of skin cleaners. . Documentation requirements. Hair dyes. anti ageing creams. Development of Cosmetic Products. lip colour. Knowledge of the Legal/Regulatory Standards/Systems governing Cosmetic products Indian as well as International. acne products. Raw materials used for Cosmetic preparation: Detailed knowledge of various raw materials used in cosmetic industry. Good Manufacturing Practices and Regulatory Requirements.I. humectants.

. 10. Knowledge of the various microbial contaminants in cosmetic products. Compatibility and stability testing of packaging materials in cosmetic products. Antiperspirants and deodorants. Efficacy and safety testing of preservatives in cosmetic products. Personal Hygiene Products: Shaving creams and after shave products. Knowledge of various preservative systems for cosmetic products. Safety testing of Cosmetic Products: Microbiology in Cosmetics. Selection criteria for preservatives. Knowledge of various machines used for packing of cosmetic products. Contemporary trends in cosmetics packaging. 9. Packaging in Cosmetics: Knowledge of various Packaging materials used in cosmetic products.8.

Needleman and Wunsch algorithms. 4.II. QSAR with computers. Databases: Biological databases. CoMFA & CoMSIA: Introduction. 3.ELECTIVES OF II SEMESTER M. QSAR and computer applications.1. statistical methods. CLUSTAL Sequence database. Reaction data bases. Unknown receptors: Pharmacophore v/s binding site models. multiple sequence alignment. 2D and 3D data bases.ELE. parameters. conclusions. Dsi-BLAST Pairwise sequence alignment. homolog y modeling. finding the common pattern. known receptors: Definition of site. Chem. calculation of affinity. design of ligands.. COMPUTER AIDED DRUG DESIGN Database and software systems. 1. DBS-3D MACCS 3D. c-logp. sybyl/3DB. 3D-QSAR approaches. summary and conclusions. Soft ware systems: Cambridge structural database. similarity searches: BLAST. PAM. BLOSUM. Quantitative models. Sequence Analysis: Sequence comparison algorithms. Rational drug Design. 2. Smith Waterman algorithm. . Unity (Tripos) Thorn/Merlin. GONNET database. molecular comparison.T. searching for similarity. synthetic reaction information management software. chemical databases. characterization of site. FASTA. Molecular modeling Introduction. Design of Test series on QSAR. sequence comparison scoring systems.

PIPELINES.(a) Genomics and proteomic Expressed sequence Tags : Clusting and Assembly Target selection/design. data resources. DATABASES. . pharmacogenomics principles. Proteomics: 2D gel data: image analysis. integration data validations. statistical analysis. DNA sequencing. analysis. Genomics: Data production and data flow: mapping. information. Transcriptional profiling. GENE PREDICTION: AB INITIO AND SIMILARITY BASED GENOME ANNOTATION. peptide sequence determination. data validation. generations of scaffolds and contigs.

parasympathomimetics. cell-line. Preclinical and clinical models employed in the screening of new drugs belonging to following categories Antifertility agents. parametric and non parametric tests. insulin. sedatives. 2. Introduction to biostatistics. antianxiety agents. anthelmintics. oxytocin. bronchodilators. antiatherosclerotic drugs. techniques and strategies used in new drug discovery. Acetylcholine. antiarrhytamic agents. molecular biology techniques. models for status epilepticus. transgenic animals and other genetically prone animal models. antiParkinsoinan agents. eicoganoids. d-tubocurarine. Biological standardization of vaccines and sera. infarction.T. SCREENING METHODS IN PHARMACOLOGY AND CLINICAL RESEARCH 1. human genomics. ED50. intracerebroventricular and other newer techniques of drug administration and development. robotics and economics of drug discovery. in-vitro models. official bioassays. Rabies and plague. sympathomimetics. antimalarials. Antipsychotic agents. hypnotics. Bioassays: Basic principles of bioassays.2.II. HCG.ELE. cardiotonic agents. High throughput screening. hyaluronidase. vasopressin. Principles of toxicity evaluations. experimental models and statistical designs employed in biological standardization. patch-clamp technique. antiepileptics. antiulcer agents. . antidepressant drugs. 4. LD50 and TD values. muscle relaxants (both central and peripheral). b. Drug discovery process: Principles. nootropic drugs. antidiabetics. International guidelines (ICH recommendations). c.M. antihistaminics. cardiac stimulants. Adrenaline. a. analgesics and anti-inflammatory agents. pertussis. Alternatives to animal screening procedures. 3. Regulations for laboratory animal care and ethical requirements. corticotrophine.

DRUG AND DRUG PRODUCTS STABILITY Overview of kinetic concepts – First. catalysis. inhibition of oxidation c) Photolysis Energetics of photolysis Kinetics of photolysis Photolytic reactions of Pharmaceutical interest Prevention of photolytic reactions stabilization of b) 7. Temperature as a stress : Arrhenius theory.ELE. Serires. structure and utility.M.T. consecutive and reversible reaction. media effects . Oxidation Nature of oxidation Kinetics of oxidation Oxidation pathways of Pharmaceutical interest. activation energy calculations. equations and their application. 1.II. pH effects. Stability prediction by pharmacist and calculation protocols. pharmaceuticals. 5. 2. 4. pharmaceutical examples. drugexcipient and drug-drug interaction in solid state methods of stabilization. 3. Drug decomposition mechanisms: a) Hydrolysis and acyltransfers. 2nd . Q10 value calculations. .3. Interpretation of kinetic data: Transition state theory. Complex order kinetics – concepts. Nature of reaction. and pseudo orders. steady state approximation. Some practical applications. Solid state chemical decomposition Kinetics of solid state decomposition Pharmaceutical examples of solid state decomposition pure drugs. 6.

9. niosomes and nano particles. liposomes. (A) (B) (C) (D) Regulatory requirements Stability protocols Experimental design Interpretation of data . powder and granules Disperse systems Microbial decomposition Over view. capsules. physical stability of novel drug carriers.8. Strategy and tactics of stability testing. Physical stability testing of dosage forms (1) (2) (3) (4) Solids – tablets.

Techniques of immobilization of enzymes and cells and their applications in the industry. Hybridoma techniques – fusion methods for myeloma cells and BLymphocytes. Fed batch and continuous systems. Classification of immunologicals. D. Manufacture techniques for bacterial and viral vaccines. amylase and trypsin and papain. Vaccinology – knowledge of Extended programme of Immunisation. Single cell protein for food and feed. newer delivery systems. PHARMACEUTICAL BIOTECHNOLOGY 1. Classification. Naked DNA vaccines. 3. Aerobic and Anaerobic fermentation: The design of a fermenter for the fermentations. E. extraction and purification. general properties of enzymes. sub . dynamics of enzymatic activity. Microbial biotechnology A. adjuvants. C.4. Production of amylo glucosidase. Microbial production of bio degradable plastics. C. Reactors for immobilized enzyme systems. sources of enzymes. Bio degradation of xenobiotics. B. glucose isomerase. D. D. Bio transformation of steroids and for the synthesis of chiral drugs and production of optically pure L and D aminoacids.II. Enzyme technology: B.M. Living and nonliving antigens.T. Production and purification of monoclonal antibodies and their applications in clinical diagnosis. Immunobiotechnology: B. Immunopotenciation. therapeutic and clinical. Immuno diagnosis of infectious diseases and diagnostic agents. Antibiotic fermentations of penicillin and Rifamipicin in detail and a brief knowledge of peptide antibiotics.ELE. immunotherapy and pharmaceutical research. Applications – Pharmaceutical. selection and screening techniques. C. 2.

. C. Applications of the above techniques in the production of i) ii) iii) iv) F. polymerase are chain reaction and analysis of DNA sequences. Signal transduction. recombinant selection and screening – expression in E-coli and yeasts. DNA technology: B. The human genome project . Animal cell culture – General Requirements for establishing the animal cell culture.4. Genetic engineering: Techniques of gene manipulation. procedures. 6. conditions and methods for cell cultures. Bio informatics: A brief knowledge of bio-informatics and its use in pharmacy and medicine. B. expression vectors. interferon. Blood products – erythropoietin. Knowledge of site directed mutagenesis. cloning strategies. D. Production of useful proteins in transgenic animals and gene therapy and restriction fragment length polymorphisms (RFLP) in diagnosis. tPA Vaccines – Hepatitis B Hormones – Insulin Study on controlled and site specific delivery of therapeutic peptides and proteins through various routes of administration. E. regulatory proteins. Plant tissue culture: General requirements for establishing the plant tissue culture system and their application for pharmaceuticals. Cell culture technology: A. media. G. 5. oncogenes and their proteins. Gene library and DNA. etc. interleukins.a brief study. H. Applications in Pharmacy. I. cloning vectors.

SYLLABUS FOR M.PHARMACY COURSE (2 YEARS DURATION) REVISED 2003 – 2004 WITH MINOR MODIFICATIONS EFFECTIVE FROM 2004-2005 ACADEMIC YEAR ONWARDS KAKATIYA UNIVERSITY WARANGAL – 506 009 .